Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Aug 2010 · 1 min read
In brief
In brief
This preclinical study demonstrates that CP-31398 inhibits rhabdomyosarcoma growth in both wild-type and mutant p53 tumors through mitochondrial-mediated apoptosis and reactive oxygen species generation. The compound reduced tumor xenograft growth and improved survival in animal models, suggesting potential as a therapeutic strategy for this pediatric soft-tissue sarcoma.
Written by the GCMD Library team from the article.
Statements in this article
Rhabdomyosarcoma is a common soft-tissue sarcoma of childhood in need of more effective therapeutic options.
The expression of p53 in rhabdomyosarcoma is heterogeneous such that some tumors are wild-type whereas others are p53 mutant.
CP-31398 blocks the growth of rhabdomyosarcoma cells that have either wild-type or mutant p53 status.
In wild-type A204 cells, CP-31398 increased the expression of p53 and its downstream transcriptional targets, p21 and mdm2.
CP-31398 enhanced the expression of apoptosis-related proteins and reduced proliferation biomarkers in wild-type A204 cells.
Flow profiling of CP-31398-treated cells indicated an enhancement in sub-G0 and G1 populations.
CP-31398 inhibited proliferation in a manner associated with co-induction of SOX9 and p21.
Apoptosis induced by CP-31398 occurred with translocation of p53 to mitochondria, leading to altered mitochondrial membrane potential, cytochrome c release, and reactive oxygen species release.
CP-31398 decreased the growth of tumor xenografts composed of wild-type or mutant p53 tumor cells in vivo.
CP-31398 increased tumor-free host survival in xenograft models.
The ability of CP-31398 to modulate wild-type and mutant p53 results in the inhibition of rhabdomyosarcoma growth and invasiveness.